USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
18 Jan 2023 | 03:45 PM GMT

Increase DTx Market Access and Adoption via Precision Patient Engagement

Anchored by:

Bob Gold
Founder and Chief Behavioral Technologist
GOMO HEALTH

Participants:

Bob Gold Founder and Chief Behavioral TechnologistGoMo Health
Bob Gold
Founder and Chief Behavioral TechnologistGoMo Health
Fulvio Michelis Digital Strategy DirectorMerck KGaA
Fulvio Michelis
Digital Strategy DirectorMerck KGaA
Kevin Darcy Director, Link StrategyVeeva
Kevin Darcy
Director, Link StrategyVeeva
Marta Sole Venture Innovation ManagerMon Clinic
Marta Sole
Venture Innovation ManagerMon Clinic
Maya Desai Board MemberGuidehouse
Maya Desai
Board MemberGuidehouse
Patrick Leyseele Founder3.life
Patrick Leyseele
Founder3.life
Rick Bartels President/Founder DTxCC
Rick Bartels
President/Founder DTxCC
Simon Bock Market Access ManagerTiefenbacher Pharmaceuticals
Simon Bock
Market Access ManagerTiefenbacher Pharmaceuticals

About this Meeting

Small, intimate and participant-led discussions tackling digital health challenges. Spaces are limited to 8 - 12 people, allowing you to focus on quality in-depth conversations.

*This meeting is not just focused on FDA approved/prescription-based DTx solutions, but also companions to medication therapy or a digital therapy itself.* 
 
Market access and adoption are huge challenges in the DTx and Pharma/Life Sciences industry. Building precise patient engagement strategies is key to drive adoption, hence better health outcomes, which will ultimately help increase market access. Personalization is key for DTx companies to deliver the right messages and therapies to the right patient and at the right time. In this meeting, we will focus on how we can use precision patient engagement to personalise the experience and increase market access and adoption. Join to discuss: 
 
  • Engaging the person, not just the disease. Not all patients with the same disease are the same. How can DTx companies ensure they focus on the person rather than the disease? 
  • The use of behavioural science for more precise patient engagement strategies. How can we use evidence-based behavioural and cognitive science to engage and activate patients? Why does this approach work and how can we successfully use it to customise the experience for each patient? 
  • The impact of patient engagement on DTx market access. How can DTx companies leverage precision patient engagement to improve health outcomes and collect RWE that supports conversations with payers? What engagement data points should DTx suppliers use to show costs’ reductions, and get payers to cover as much as possible?
  • The importance of human interaction in patient engagement with digital therapies.
  • Personalization vs. Scaling. Is personalization possible when scaling? 
We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.